What is the share price of Concord Drugs Ltd (CONCORD) today?
The share price of CONCORD as on 23rd June 2025 is ₹29.99. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Concord Drugs Ltd (CONCORD) share?
The past returns of Concord Drugs Ltd (CONCORD) share are- Past 1 week: -1.36%
- Past 1 month: -3.24%
- Past 3 months: -12.12%
- Past 6 months: -20.30%
- Past 1 year: -24.07%
- Past 3 years: 21.23%
- Past 5 years: 78.91%
What are the peers or stocks similar to Concord Drugs Ltd (CONCORD)?
The peers or stocks similar to Concord Drugs Ltd (CONCORD) include:What is the market cap of Concord Drugs Ltd (CONCORD) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Concord Drugs Ltd (CONCORD) is ₹30.48 Cr as of 23rd June 2025.What is the 52 week high and low of Concord Drugs Ltd (CONCORD) share?
The 52-week high of Concord Drugs Ltd (CONCORD) is ₹44.96 and the 52-week low is ₹26.10.What is the PE and PB ratio of Concord Drugs Ltd (CONCORD) stock?
The P/E (price-to-earnings) ratio of Concord Drugs Ltd (CONCORD) is 89.65. The P/B (price-to-book) ratio is 0.90.Which sector does Concord Drugs Ltd (CONCORD) belong to?
Concord Drugs Ltd (CONCORD) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Concord Drugs Ltd (CONCORD) shares?
You can directly buy Concord Drugs Ltd (CONCORD) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Concord Drugs Ltd
CONCORD Share Price
29.991.51% (-0.46)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
CONCORD Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
CONCORD Performance & Key Metrics
CONCORD Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 98.32 | 0.90 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.51 | 6.52 | 0.85% |
CONCORD Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
CONCORD Company Profile
Concord Drugs is a pharmaceutical company, engaged in the manufacture of pharmaceutical formulations and the trading of packing material
SUNPHARMA
PE Ratio
36.56
36.56
1Y Return
11.24%
11.24%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
22.97
22.97
1Y Return
0.35%
0.35%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
19.50
19.50
1Y Return
8.83%
8.83%
Buy Reco %
56.67
56.67
TORNTPHARM
PE Ratio
56.09
56.09
1Y Return
11.44%
11.44%
Buy Reco %
72.00
72.00
ZYDUSLIFE
PE Ratio
21.28
21.28
1Y Return
12.08%
12.08%
Buy Reco %
46.43
46.43
CONCORD Forecast
CONCORD Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
CONCORD
CONCORD
Income
Balance Sheet
Cash Flow
Annual Normal View
CONCORD Income Statement
CONCORD Income Statement
Annual Normal View
| Financial Year | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 59.06 | 52.09 | 44.93 | 45.26 | 45.26 | |||||
Raw Materials | 44.41 | 41.16 | 31.10 | 41.11 | 41.11 | |||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | |||||||
| Employee Cost | 4.14 | 3.84 | 5.00 | |||||||
| Selling & Administrative Expenses | 1.53 | 2.14 | 2.06 | |||||||
| Operating & Other expenses | 3.28 | 0.36 | 2.73 | |||||||
EBITDA | 5.70 | 4.59 | 4.04 | 4.15 | 4.15 | |||||
| Depreciation/Amortization | 1.76 | 1.63 | 1.56 | 1.43 | 1.43 | |||||
| PBIT | 3.94 | 2.96 | 2.48 | 2.72 | 2.72 | |||||
| Interest & Other Items | 1.68 | 1.71 | 1.87 | 2.03 | 2.03 | |||||
| PBT | 2.26 | 1.25 | 0.61 | 0.69 | 0.69 | |||||
| Taxes & Other Items | 0.65 | 0.26 | 0.16 | 0.35 | 0.38 | |||||
| Net Income | 1.61 | 0.99 | 0.45 | 0.34 | 0.31 | |||||
| EPS | 1.84 | 1.10 | 0.47 | 0.34 | 0.31 | |||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
CONCORD Company Updates
CONCORD Stock Peers
CONCORD Past Performance & Peer Comparison
CONCORD Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Concord Drugs Ltd | 89.65 | 0.90 | — |
| Sun Pharmaceutical Industries Ltd | 36.56 | 5.95 | 0.96% |
| Cipla Ltd | 22.97 | 4.52 | 1.07% |
| Dr Reddy's Laboratories Ltd | 19.50 | 3.90 | 0.61% |
CONCORD Stock Price Comparison
Compare CONCORD with any stock or ETFCompare CONCORD with any stock or ETF
CONCORD
CONCORD Holdings
CONCORD Shareholdings
CONCORD Promoter Holdings Trend
CONCORD Promoter Holdings Trend
CONCORD Institutional Holdings Trend
CONCORD Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
CONCORD Shareholding Pattern
CONCORD Shareholding Pattern
CONCORD Shareholding History
CONCORD Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing CONCORD stock
smallcases containing CONCORD stock
Looks like this stock is not in any smallcase yet.
CONCORD Events
CONCORD Events
CONCORD Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
CONCORD has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
CONCORD Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
CONCORD has not given any dividends in last 5 years
CONCORD Dividends
CONCORD Dividends
Hmm, looks like data is unavailable here. Please come back after some timeCONCORD Stock News & Opinions
CONCORD Stock News & Opinions
Articles & Videos
Corporate
Concord Drugs to hold board meeting
Concord Drugs will hold a meeting of the Board of Directors of the Company on 27 June 2025.Powered by Capital Market - Live
3 days agoCapital Market - Live
Earnings
Concord Drugs reports consolidated net profit of Rs 0.04 crore in the March 2025 quarter
Net profit of Concord Drugs reported to Rs 0.04 crore in the quarter ended March 2025 as against net loss of Rs 0.34 crore during the previous quarter ended March 2024. Sales declined 33.57% to Rs 10.39 crore in the quarter ended March 2025 as against Rs 15.64 crore during the previous quarter ended March 2024. For the full year,net profit declined 27.66% to Rs 0.34 crore in the year ended March 2025 as against Rs 0.47 crore during the previous year ended March 2024. Sales rose 0.71% to Rs 45.24 crore in the year ended March 2025 as against Rs 44.92 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales10.3915.64 -34 45.2444.92 1 OPM %10.112.24 -9.179.02 - PBDT0.44-0.15 LP 2.122.18 -3 PBT0.06-0.55 LP 0.690.63 10 NP0.04-0.34 LP 0.340.47 -28 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Concord Drugs to announce Quarterly Result
Concord Drugs will hold a meeting of the Board of Directors of the Company on 23 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Concord Drugs postpones board meeting
Concord Drugs has postponed the meeting of the Board of Directors which was scheduled to be held on 13 March 2025. The meeting will now be held on 17 March 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Concord Drugs to convene board meeting
Concord Drugs will hold a meeting of the Board of Directors of the Company on 13 March 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Concord Drugs reports consolidated net profit of Rs 0.23 crore in the December 2024 quarter
Net profit of Concord Drugs reported to Rs 0.23 crore in the quarter ended December 2024 as against net loss of Rs 0.24 crore during the previous quarter ended December 2023. Sales declined 15.49% to Rs 10.80 crore in the quarter ended December 2024 as against Rs 12.78 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales10.8012.78 -15 OPM %12.874.93 - PBDT0.900.13 592 PBT0.53-0.26 LP NP0.23-0.24 LP Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Concord Drugs to table results
Concord Drugs will hold a meeting of the Board of Directors of the Company on 11 January 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Concord Drugs consolidated net profit declines 92.86% in the September 2024 quarter
Net profit of Concord Drugs declined 92.86% to Rs 0.04 crore in the quarter ended September 2024 as against Rs 0.56 crore during the previous quarter ended September 2023. Sales rose 64.36% to Rs 12.36 crore in the quarter ended September 2024 as against Rs 7.52 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales12.367.52 64 OPM %7.1221.41 - PBDT0.411.19 -66 PBT0.070.80 -91 NP0.040.56 -93 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Concord Drugs announces board meeting date
Concord Drugs will hold a meeting of the Board of Directors of the Company on 13 November 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Concord Drugs to conduct AGM
Concord Drugs announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant